Retrospective Cohort Study of the Prevalence of Off-label Gabapentinoid Prescriptions in Hospitalized Medical Patients

Marc-Alexandre Gingras, Anthony Lieu, Louise Papillon-Ferland, Todd C Lee, Emily G McDonald, Marc-Alexandre Gingras, Anthony Lieu, Louise Papillon-Ferland, Todd C Lee, Emily G McDonald

Abstract

Gabapentinoid prescriptions are increasing in North America, with frequent off-label use despite limited proven efficacy. This retrospective cohort study describes prescribing trends among hospitalized patients with a focus on dosing and deprescribing. We examined consecutive inpatients between December 2013 and July 2017 on a 52-bed medical unit in Montréal, Canada. Prevalence of off-label use, median doses prescribed, and deprescribing trends were analyzed over time. Of 4,103 hospitalized patients, 550 (13.4%) were prescribed gabapentinoids preadmission, with two patients being coprescribed gabapentin and pregabalin (total 552 prescriptions). A minority (94/552, or 17%) were for approved indications. Although it was uncommon for gabapentinoids to be newly prescribed in hospital, preadmission gabapentinoids were also seldom deprescribed (65/495 patients discharged alive, or 13%). Given a high prevalence of use, limited efficacy, and potential harms, gabapentinoids may represent an ideal target for re-evaluation of indication and effectiveness in hospitalized adults, with consideration given to deprescribing.

© 2019 Society of Hospital Medicine.

References

    1. Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178(2):292–294. doi: 10.1001/jamainternmed.2017.7856.
    1. Kwok H, Khuu W, Fernandes K, et al. Impact of unrestricted access to pregabalin on the use of opioids and other CNS-active medications: a cross-sectional time series analysis. Pain Med. 2017;18(6):1019–1026. doi: 10.1093/pm/pnw351.
    1. Medicines use and spending in the U.S.—a review of 2016 and outlook to 2021. IMS Institute for Healthcare Informatics; 2017. [Accessed March 21, 2019]. .
    1. Hamer AM, Haxby DG, McFarland BH, Ketchum K. Gabapentin use in a managed medicaid population. J Manag Care Pharm. 2002;8(4):266–271. doi: 10.18553/jmcp.2002.8.4.266.
    1. Eguale T, Buckeridge DL, Verma A, et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2016;176(1):55–63. doi: 10.1001/jamainternmed.2015.6058.
    1. Shanthanna H, Gilron I, Rajarathinam M, et al. Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2017;14(8):e1002369. doi: 10.1371/journal.pmed.1002369.
    1. Enke O, New HA, New CH, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ. 2018;190(26):E786–E793. doi: 10.1503/cmaj.171333.
    1. Kane CM, Mulvey MR, Wright S, Craigs C, Wright JM, Bennett MI. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: systematic review and meta-analysis. Palliat Med. 2018;32(1):276–286. doi: 10.1177/0269216317711826.
    1. Zaccara G, Perucca P, Gangemi PF. The adverse event profile of pregabalin across different disorders: a meta-analysis. Eur J Clin Pharmacol. 2012;68(6):903–912. doi: 10.1007/s00228-012-1213-x.
    1. Huang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging. 2012;29(5):359–376. doi: 10.2165/11599460-000000000-00000.
    1. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403–426. doi: 10.1007/s40265-017-0700-x.
    1. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. doi: 10.1371/journal.pmed.1002396.
    1. McDonald EG, Saleh RR, Lee TC. Ezetimibe use remains common among medical inpatients. Am J Med. 2015;128(2):193–195. doi: 10.1016/j.amjmed.2014.10.016.
    1. Food US. Drug Administration. LYRICA-Highlights of Prescribing Information; 2012. [Accessed April 30, 2019]. .
    1. US Food and Drug Administration [Accessed April 30, 2019];NEURONTIN-Highlights of Prescribing Information. 2017 .
    1. Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case–control study. Ann Intern Med. 2018;169(10):732–734. doi: 10.7326/M18-1136.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel